Gilead Sciences, Inc.

Amygdala Neurosciences, Inc.

Robert G Strickley

Jeff A Zablocki

Michael Graupe

Chandrasekar Venkataramani

Juan A Guerrero

Carina E Cannizzaro

Yafan Lu

Bing Shi

Chiajen Lai

Nate Larson

Reza Oliyai

Mark Michael Menning

Richard Yu

Joanna M Koziara

Brian P Kearney

Anita A Mathias

Mark M Menning

The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.

Crystalline forms of tenofovir alafenamide

The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections

Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Compounds for the treatment of addiction

The invention provides a composition comprising, a compound of formula (I): or a pharmaceutically acceptable salt thereof and a plurality of solid carrier particles, as well as methods for using the composition to inhibit the activity of cytochrome P-450.

Use of solid carrier particles to improve the processability of a pharmaceutical agent

Disclosed are novel compounds having the structure of Formula (I): which are useful for treating a human for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Growing community of inventors

San Mateo, CA, United States of America

Robert G Strickley